The Intelligence from The Economist Wary pharma: AstraZeneca sours on UK
17 snips
Sep 18, 2025 In this episode, reporter Claire McHugh shares insights on AstraZeneca's surprising pause on its UK investment and the implications for the country's status in the life sciences. The conversation shifts to the future of warfare with advancements in autonomous drone technology. McHugh also discusses innovative coral IVF techniques being utilized in Colombia, including underwater spawning and genetic preservation efforts aimed at reviving damaged reefs. This blend of industry and environmental topics makes for an engaging listen.
AI Snips
Chapters
Transcript
Episode notes
AstraZeneca's Warning Sign
- AstraZeneca has paused a £200m Cambridge investment and is weighing a primary listing move to New York.
- That signals Britain may be losing momentum as a global life-sciences hub despite its scientific strengths.
Policy Friction Undermining UK Appeal
- Drug companies complain UK policies like high clawback taxes and strict NICE decisions reduce commercial incentives.
- These factors make the US market comparatively more attractive despite claims investments aren't tariff-driven.
Market Size Drives Investment Shifts
- Big pharma is shifting focus to the US because of its sheer market size and growth.
- The UK's share of global pharma R&D and clinical trials has fallen while other countries expand.